Last reviewed · How we verify
Magnesium Sulfate In Dextrose 5% In Plastic Container (Magnesium Sulfate)
Magnesium Sulfate In Dextrose 5% In Plastic Container (generic name: Magnesium Sulfate) is a Anticonvulsant Small molecule drug developed by Pfizer Inc.. It is currently FDA-approved for Prevention of eclampsia in patients with preeclampsia, Treatment of seizures, Prevention of recurrent seizures in patients with eclampsia.
Magnesium Sulfate blocks neuromuscular transmission and decreases acetylcholine levels, leading to vasodilation and a depressant effect on the central nervous system.
Magnesium Sulfate is a medication used to prevent eclampsia in patients with preeclampsia, treat seizures, and prevent recurrent seizures in patients with eclampsia. It is marketed by Pfizer Inc. Magnesium Sulfate works by blocking neuromuscular transmission and decreasing acetylcholine levels. This leads to vasodilation and a depressant effect on the central nervous system. The medication is a white crystalline solid, soluble in water, and consists of magnesium cations and sulfate anions. It has a significant clinical differentiation due to its unique mechanism of action. Magnesium Sulfate has a commercial significance due to its widespread use in treating preeclampsia and eclampsia. There are no notable pipeline developments for this medication.
At a glance
| Generic name | Magnesium Sulfate |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Anticonvulsant |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Magnesium Sulfate works by blocking the release of acetylcholine at the neuromuscular junction, which leads to a decrease in muscle contraction and a subsequent decrease in blood pressure. This effect is due to the magnesium ions binding to the acetylcholine receptors, preventing the release of acetylcholine. Additionally, magnesium has a depressant effect on the central nervous system, which can lead to a decrease in the frequency and severity of seizures.
Approved indications
- Prevention of eclampsia in patients with preeclampsia
- Treatment of seizures
- Prevention of recurrent seizures in patients with eclampsia
Common side effects
- hypotension
- circulatory collapse
- cardiac depression including bradycardia
- central nervous system depression leading to respiratory paralysis
- visual disturbances
- flushing
- sweating
- hypothermia
- hypocalcemia with signs of tetany
- hypermagnesemia
- lethargy
- sedation
Drug interactions
- Neuromuscular Blocking Agents
- Narcotics and/or Propofol
- Dihydropyridine Calcium Channel Blockers
- Alcohol
- Aminoglycosides
- Amphotericin B
- Cisplatin
- Cyclosporine
- Digitalis
- Loop Diuretics
- Thiazide Diuretics
- Succinylcholine
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
- Comparison of Fentanyl and Magnesium to Control Reflex Hemodynamics in Patients Aged 50 and Older (NA)
- Biomarkers in Management of Post Partum Preeclampsia (PHASE4)
- Comparison of Mean Duration of Analgesia Following the Administration of Bupivacaine With and Without Magnesium Sulphate in Ultrasound Guided Erector Spinae Plane Block in Modified Radical Mastectomy Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium Sulfate In Dextrose 5% In Plastic Container CI brief — competitive landscape report
- Magnesium Sulfate In Dextrose 5% In Plastic Container updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Magnesium Sulfate In Dextrose 5% In Plastic Container
What is Magnesium Sulfate In Dextrose 5% In Plastic Container?
How does Magnesium Sulfate In Dextrose 5% In Plastic Container work?
What is Magnesium Sulfate In Dextrose 5% In Plastic Container used for?
Who makes Magnesium Sulfate In Dextrose 5% In Plastic Container?
What is the generic name of Magnesium Sulfate In Dextrose 5% In Plastic Container?
What drug class is Magnesium Sulfate In Dextrose 5% In Plastic Container in?
What development phase is Magnesium Sulfate In Dextrose 5% In Plastic Container in?
What are the side effects of Magnesium Sulfate In Dextrose 5% In Plastic Container?
What does Magnesium Sulfate In Dextrose 5% In Plastic Container target?
Related
- Drug class: All Anticonvulsant drugs
- Target: All drugs targeting Nicotinic acetylcholine receptor
- Manufacturer: Pfizer Inc. — full pipeline
- Indication: Drugs for Prevention of eclampsia in patients with preeclampsia
- Indication: Drugs for Treatment of seizures
- Indication: Drugs for Prevention of recurrent seizures in patients with eclampsia
- Compare: Magnesium Sulfate In Dextrose 5% In Plastic Container vs similar drugs
- Pricing: Magnesium Sulfate In Dextrose 5% In Plastic Container cost, discount & access